Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of “Buy” from Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $21.57.

Several equities analysts have recently issued reports on the company. Maxim Group upped their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Roth Mkm lifted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Zevra Therapeutics in a research report on Wednesday, January 8th. They issued an “overweight” rating and a $25.00 price objective on the stock.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $8.05 on Tuesday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $429.71 million, a PE ratio of -4.09 and a beta of 2.01. The stock’s fifty day simple moving average is $8.68 and its two-hundred day simple moving average is $7.80. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the business earned ($0.40) earnings per share. As a group, analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC raised its stake in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the period. Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter worth about $92,000. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $94,000. Finally, Intech Investment Management LLC bought a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $95,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.